22
Aug
2022
A Life in Autoimmune Drug Discovery: Jo Viney on The Long Run
Today’s guest on The Long Run is Jo Viney. She is the CEO of Watertown, Mass.-based Seismic Therapeutic. Seismic is working to discover biologic drugs for autoimmune disease. It aims to speed up the process by using machine learning on key aspects – starting with structural biology and including engineering of the protein drugs themselves. Jo has a long track... Read More
11
Aug
2022
Karuna’s Schizophrenia Advance, FDA Clears HER2-Low Drug, & Pfizer Buys GBT
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Aug
2022
Assembling Accurate Genomes and Interactomes: Ivan Liachko on The Long Run
Today’s guest on The Long Run is Ivan Liachko. Ivan the founder and CEO of Seattle-based Phase Genomics. First off, Ivan is originally from Kiev, Ukraine. He came with his family to the US at the age of 11, around the time of the fall of the old Soviet Union. When Russia invaded Ukraine back in February, he spoke up... Read More
4
Aug
2022
Alnylam’s Big Day, Amgen Buys ChemoCentryx & a Borisy Startup
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Aug
2022
ElevateBio, Boston Children’s Form Startup to Turn iPSCs Into Mature T-cells for Cancer
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Jul
2022
Novavax Cleared, Verve’s Gene Editing Milestone, & Third Rock Reaches Out
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Jul
2022
Restoring Eyesight in the Developing World: Dr. Sanduk Ruit on The Long Run
Today’s guest on The Long Run is Dr. Sanduk Ruit. He is an ophthalmologist and the founder and executive director of the Tilganga Institute of Ophthalmology. The institute is in Kathmandu, Nepal. Dr. Ruit has restored the eyesight of more than 130,000 people in Asia and Africa. He’s the pioneer of a small-incision form of cataract surgery. Not only was... Read More
7
Jul
2022
Merck Circles Seagen, Arch Triples Down & Novartis Cuts 8,000 Jobs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Jun
2022
Recode Therapeutics Pockets Extra $120M for Targeted Genetic Medicine Delivery
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Jun
2022
Nucleate Doubles in Size, Enabling Young Scientists’ Entrepreneurial Dreams
Academia has a tradition of doing nothing, or next to nothing, to educate and encourage young people to learn about entrepreneurship. But whether academia wants it or not, it’s coming. Young scientists are taking matters into their own hands, organizing themselves in many major research hubs. Nucleate, the nonprofit providing free resources to empower a new generation of biotech entrepreneurs,... Read More
23
Jun
2022
Clinical Trials That Deliver Better Social and Financial Returns
Sometimes doing the right thing requires sacrifice. Other times, the right thing for human health can also be a shrewd business move. That was the intriguing result of a study on the returns sponsors can expect from decentralized trials. The study relied on data from Medable and the Tufts Center for the Study of Drug Development. Results were presented this... Read More
22
Jun
2022
Bringing Precision Medicine to Neuro: Ivana Magovcevic-Liebisch on The Long Run
Today’s guest on The Long Run is Ivana Magovcevic-Liebisch She is the CEO of Cambridge, Mass.-based Vigil Neuroscience. The story starts with Amgen. The big biotech made a strategic decision to get out of neuroscience in 2019. That meant a couple of drug programs targeting TREM2 came up for sale. One is a monoclonal antibody, and the other is a... Read More
16
Jun
2022
Day One Shines, Third Rock Carries On and Vertex/CRISPR Deliver
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Jun
2022
Third Rock Raises $1.1B Fund, Sticks With Its Knitting in a Downturn
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Jun
2022
Seattle Children’s Invests $45M in Minority Scientists Tackling Pediatric Disease
Many bright young people never get a chance to fulfill their potential as scientists because they never get on the usual scientific career on-ramps. Many young people who get sick struggle because no one had the motivation or the wherewithal to develop new treatments or diagnostics. Seattle Children’s Research Institute sees the problems, and has crafted a major initiative to... Read More
12
Jun
2022
Day One Shrinks Brain Tumors for Kids, Gears Up for First-Line Study
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Jun
2022
Daiichi’s Game-Changer, Resilience’s Big Week, and the FTC Scrutinizes PBMs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Jun
2022
Rethinking Biotech Manufacturing: Rahul Singhvi on The Long Run
Today’s guest on The Long Run is Rahul Singhvi. Rahul is the co-founder and CEO of Resilience. The company made a splash in the fall of 2020, when it debuted with an $800 million Series A financing. Bob Nelsen of ARCH Venture Partners led the deal. The company has now raised a couple more rounds that add up to more... Read More
2
Jun
2022
Out in the Community in 2022
TR subscribers: I’m traveling more, and looking forward to seeing more of you in person. I’ll be at the BIO Convention in San Diego, June 13-15. They have plenty of outdoor patio space overlooking the ocean at the San Diego Convention Center. Let’s chat. While at BIO meeting people and gathering ideas, I’m also moderating a panel on improving diversity,... Read More
2
Jun
2022
Startup Profiles: Upstream Gets $200m for Asthma Antibody; Transition Fetches $50m for Condensate Drug Discovery
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.